Exploring Health Care's Frontier: Biotech, GLP-1s and Global Pricing Dynamics
Description
From biotech's rebound to the next frontier for GLP-1 drugmakers, Chendhore Veerappan, PhD, CFA, our health care research analyst, delves into the trends and investment opportunities unfolding in this dynamic sector. Tune in to our latest podcast!
As of 30 April 2024, Diamond Hill owned shares of Abbott Laboratories and Roche Holdings AG.
SPDR® S&P® Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P® Biotechnology Select IndustryTM Index.
The views expressed are those of Diamond Hill as of May 2024 and are subject to change without notice. These opinions are not intended to be a forecast of future events, a guarantee of future results or investment advice. Investing involves risk, including the possible loss of principal. Past performance is not a guarantee of future results.
United States
